Drug Profile

Ropivacaine extended release - PainReform

Alternative Names: PRF 110; PRF-110-oily solution

Latest Information Update: 04 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PainReform
Class Amides; Anilides; Local anaesthetics; Non-opioid analgesics; Piperidines; Small molecules
Mechanism of Action Potassium channel antagonists; Sodium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase III Postoperative pain

Most Recent Events

30 Aug 2024 PainReform completes a phase-III clinical trials in Postoperative pain in USA (Parenteral) (NCT05773846)
13 Mar 2023 Phase-III clinical trials in Postoperative pain in USA (Parenteral) (NCT05773846)
18 Jul 2018 US FDA grants approval to conduct two pivotal phase III trials for extended release ropivacaine for Post-operative pain

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com